MKGAF - Merck Kommanditgesellschaft auf Aktien

Other OTC - Other OTC Delayed price. Currency in USD
111.37
+0.11 (+0.10%)
At close: 11:06AM EDT
Stock chart is not supported by your current browser
Previous close111.26
Open111.37
Bid0.00 x 0
Ask0.00 x 0
Day's range111.37 - 111.37
52-week range97.56 - 124.40
Volume50
Avg. volume89
Market cap46.66B
Beta0.72
PE ratio (TTM)24.79
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & Yield1.31 (1.16%)
Ex-dividend date2017-05-02
1y target estN/A
Trade prices are not sourced from all markets
  • Reuters - UK Focuslast month

    Germany's Merck hires JP Morgan to sell consumer health

    FRANKFURT/LONDON, Sept 8 (Reuters) - Germany's Merck KGaA has hired JP Morgan to sell its consumer health business, which includes brands such as Seven Seas vitamins and could be worth around $4.5 billion. The family-controlled drugmaker said on Tuesday it was considering selling the business, whose sales of over-the-counter medicines and vitamin supplements are about $1 billion a year, to help fund research into higher-margin prescription drugs.

  • Reuters - UK Focuslast month

    Germany's Merck considers sale of consumer health business

    FRANKFURT/COLOGNE, Sept 5 (Reuters) - Germany's Merck KGaA (LSE: 0O14.L - news) is considering selling its consumer healthcare business which has sales of $1 billion a year to help fund more research into prescription drugs and amid declines in the company's separate liquid crystal business. The company said on Tuesday that to remain competitive the consumer healthcare business would need further investment and therefore it was considering a sale or strategic partnership instead, adding that a review process was at an early stage with a final decision expected to be made early next year. Fully anticipating this, we are preparing strategic options," Belen Garijo, chief executive of Merck's entire Healthcare (Shanghai: 603313.SS - news) division, said in a statement.

  • Germany’s Merck chooses Israeli deception technology
    CNBC5 months ago

    Germany’s Merck chooses Israeli deception technology

    Dark web intelligence, bio-authorization and even plain old cloud security: Cybersecurity commands a futuristic and slightly dystopian-sounding lexicon.

  • EQS Group5 months ago

    VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies

    DGAP-News: VAXIMM AG / Key word(s): Alliance09.05.2017 / 08:30 The issuer is solely responsible for the content of this announcement. ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes